Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538065 | 0.87 | MTNR1A (0.57) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL2536092 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL30961937 | 0.83 | SCN9A (0.51) | MAPT | |
| SCHEMBL2532851 | 0.82 | TRPM8 (0.66) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL13285078 | 0.80 | MTNR1A (0.56) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL2534000 | 0.80 | TYR (0.62) | MTNR1AMTNR1BMAPTALDH1A1TRPV1 | |
| SCHEMBL8957539 | 0.79 | TRPV1 (0.57) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL397159 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL2540619 | 0.79 | MTNR1A (0.57) | MTNR1AMTNR1BMEN1KMT2ATRPV1 | |
| SCHEMBL2363493 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | MTNR1A 63/4885MTNR1B 90/4885MAPT 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.